Back to results
US 11,780,898 B2Granted
Treatment of SMC mediated disease
AssigneesSingapore Health Services Pte Ltd, National University of Singapore
InventorsStuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
Life of this patent
Estimating the term…
Abstract
Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.
Claims8
A method comprising administering an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject in need thereof, wherein the subject has a disease selected from the group consisting of:
- vascular aneurysm, Marfan's syndrome, aortic aneurysm, Furlong's syndrome, Sphrintzen-Goldberg syndrome, Loeys-Dietz syndrome, familial thoracic aortic aneurysm syndrome, arterial tortuosity syndrome, cerebral aneurysm, vascular stenosis and restenosis, fibromuscular dysplasia (FMD), supravalvular stenosis, renal artery stenosis, plexiform lesions, telangiectasia, achalasia, dysphagia, diarrhoea, constipation, inflammatory bowel disease (IBD), bowel stricture, pyloric stenosis, coeliac disease, irritable bowel syndrome, diverticulitis, ulcerative colitis, focal and segmental glomerulosclerosis (FSGS), IgA nephropathy, Hutchinson-Gilford Progeria Syndrome (HGPS), leiomyoma, leiomyosarcoma and non-airway/non-lung-related pathology of Hermansky-Pudlak Syndrome (HPS), wherein the disease comprises cells having a TGFβ1-mediated pathological secretory smooth muscle cell (SMC) phenotype, and wherein the agent is an anti-IL-11 antibody or an antigen-binding fragment thereof, or an anti-IL-11Rα antibody or an antigen-binding fragment thereof.
A method for inhibiting the activity of smooth muscle cells (SMCs) in a subject in need thereof comprising:
- (a) selecting a subject who has a disease comprising cells having a TGFβ1-mediated pathological secretory smooth muscle cell (SMC) phenotype, wherein the disease is selected from the group consisting of:
- vascular aneurysm, Marfan's syndrome, aortic aneurysm, Furlong's syndrome, Sphrintzen-Goldberg syndrome, Loeys-Dietz syndrome, familial thoracic aortic aneurysm syndrome, arterial tortuosity syndrome, cerebral aneurysm, vascular stenosis and restenosis, fibromuscular dysplasia (FMD), supravalvular stenosis, renal artery stenosis, plexiform lesions, telangiectasia, achalasia, dysphagia, diarrhoea, constipation, inflammatory bowel disease (IBD), bowel stricture, pyloric stenosis, coeliac disease, irritable bowel syndrome, diverticulitis, ulcerative colitis, focal and segmental glomerulosclerosis (FSGS), IgA nephropathy, Hutchinson-Gilford Progeria Syndrome (HGPS), leiomyoma, leiomyosarcoma and non-airway/non-lung-related pathology of Hermansky-Pudlak Syndrome (HPS);
- and
- (b) administering an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to the subject, wherein the agent is an anti-IL-II antibody or an antigen-binding fragment thereof, or an anti-IL-11Rα antibody or an antigen-binding fragment thereof.
1 more element
Dependencies are inferred from the claim text.